Skip to Content

Bioqual Inc BIOQ

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Bioqual Inc is a United States-based medical research company. It is engaged in providing contract research services focused on animal models of human diseases including AIDS, influenza, RSV infection, flavivirus infections like Zika and Dengue, malaria, hepatitis, and cancer. The company is also involved in the evaluation of vaccines, vaccine therapeutics, microbicides and drug therapies. It provides the services to the federal government, universities and the life science and pharmaceutical industries. The company derives revenue from the provision of contract research services.

Contact
9600 Medical Center Drive, Suite 101
Rockville, MD, 20850-3336
T +1 240 404-7654
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Aug 31, 2011
Fiscal Year End May 31, 2019
Stock Type Aggressive Growth
Employees 117